And from the ATHE 30/6/2020 annual report filing page 2
"...as we expand our research and development and pre-clinical activities and commence clinical trials of our product candidates that includes ATH434 for Parkinsonian diseases, prospectively PBT2 for alternative indications and the development of other compounds"
- Forums
- ASX - By Stock
- PBT2 further development!
And from the ATHE 30/6/2020 annual report filing page 2"...as we...
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
77 | 96988980 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 655773 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
74 | 89988980 | 0.002 |
25 | 133640147 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 655773 | 2 |
0.004 | 151287339 | 54 |
0.005 | 8366584 | 12 |
0.006 | 16581534 | 13 |
0.007 | 53884874 | 26 |
Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online